MiMedx Welcomes Dirk Stevens, Ph.D., as Senior Vice President, Quality Assurance and Regulatory Affairs
April 28, 2021 10:21 ET | Source: MiMedx Group, Inc MiMedx Group, Inc
Accomplished Regulatory Leader Joins MiMedx Management Team
MARIETTA, Ga., April 28, 2021 (GLOBE NEWSWIRE) MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or “the Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced the addition of Dirk Stevens, Ph.D., as Senior Vice President, Quality Assurance and Regulatory Affairs, effective May 3, 2021. Dr. Stevens, who brings more than 35 years of strategic leadership experience in quality management and regulatory compliance across multiple medical device and pharmaceutical companies, joins MiMedx from Smith & Nephew, plc, where he was accountable for regulatory submissions, compliance, and Commercial Quality Assurance.
Eledon Pharmaceuticals Continues to Bolster Leadership Team with Addition of Two More Key Executives
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
INVENTIVA: Appointment of Martine Zimmermann as Independent Director to Inventiva s Board of Directors
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Investegate |INVENTIVA Announcements | INVENTIVA: Appointment of Martine Zimmermann as Independent Director to Inventiva s Board of Directors
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
BioXcel Therapeutics Appoints June Bray to Board of Directors Former Allergan executive brings extensive global regulatory experience across multiple therapeutic areas
March 01, 2021 07:00 ET | Source: BioXcel Therapeutics BioXcel Therapeutics New Haven, Connecticut, UNITED STATES
NEW HAVEN, Conn., March 01, 2021 (GLOBE NEWSWIRE) BioXcel Therapeutics, Inc. ( BioXcel or the Company ) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the appointment of June Bray to its Board of Directors. Ms. Bray brings over forty years of extensive U.S. and global regulatory experience in the healthcare industry and most recently served as Senior Vice President, Global Regulatory Affairs and Medical Writing at Allergan.